Loading
EcoR1 Capital
EcoR1 Capital is a San Francisco investment fund that only invests in biotech, from private rounds to listed companies, and often leads the crossover financings of cancer drug developers.
Overview
EcoR1 Capital is a biotech-focused investment firm based in San Francisco, founded in 2013 by Oleg Nodelman, investing across private and public companies with a long holding period and a scientific due diligence model. It is a frequent lead or co-lead in crossover rounds and follow-on offerings for clinical-stage oncology companies. Portfolio links in OnCo are derived from the startup records that name it.
Portfolio
2Portfolio (2)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Neogene Therapeutics Amsterdam, NL | Acquired | cell therapy | Acquisition 2023, $320M | |
| Tango Therapeutics Boston, MA, US | Public | biotech | Pancreatic ductal adenocarcinomaNon-small-cell lung cancerGlioma & glioblastoma | IPO 2021, $353M |
Connected
2Similar pages
- CompanyPolaris Partners
Shares Neogene Therapeutics and the tag vc.
- CompanyJeito Capital
Shares Neogene Therapeutics and the tag vc.
- CompanySamsara BioCapital
Shares Tango Therapeutics and the tag vc.
- CompanyVida Ventures
Shares Neogene Therapeutics and the tag vc.
- CompanyCormorant Asset Management
Shares Tango Therapeutics and the tag vc.
- CompanyBoxer Capital
Shares Tango Therapeutics and the tag vc.
- CompanyLogos Capital
Shares Tango Therapeutics and the tag vc.
- CompanyBain Capital Life Sciences
Shares Tango Therapeutics and the tag vc.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ecor1cap.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/